GeNeuro receives CHF 6.7 million (EUR 6.4 million) in funding from the Swiss government for the development of temelimab against Long-COVID
Geneva, Switzerland, 13 December 2021, 08:15 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final Phase II results in multiple sclerosis expected in March 2022, announced today that its development in Long-COVID is one of the four projects selected by the Swiss Federal Office […]